Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Volkan Granit(Biohaven Pharmaceuticals (United States)), Matthew T. Duvernay(Cara Therapeutics (United States)), Tuan Vu(University of South Florida), Mehmet Tosun, Charles A. Stewart(National Cancer Institute), Michael Benatar(University of Miami), Nizar Chahin(Oregon Health & Science University), Denise Pereira(Neurology Center of Southern California), James F. Howard(University of North Carolina at Chapel Hill), Julie Steele(University of South Florida), Metin Kurtoğlu, Michael S. Singer(Wesleyan University), Krishna V. Komanduri(University of Miami), Hafsa Kamboh, Yufei Shan(Yangzhou Vocational University), Christopher M. Jewell(University of Maryland, Baltimore), Gregory Sahagian(Neurology Center of Southern California), Miloš D. Miljković(Tufts University), Jerrica Farias, Tahseen Mozaffar(University of North Carolina at Chapel Hill), Adam D. Slansky(University of North Carolina at Chapel Hill), Gabrielle DeMaria, Naraly Requena, Adam Slansky(Neurology Associates), Adam Chowdhury(Neurology Associates), Julia Kimberly Fong, Ali A. Habib(University of California, Irvine Medical Center), Maria Elena Paredes, April Tenorio, Manisha Chopra, Beverly Mackanzie Brooks, Marc H. Feinberg(Boca Raton Regional Hospital), Niraja Suresh(Regional Health), S. E. Daniel(Alzheimer's Society), Diana Dimitrova, Kelly Holley, Minhtran Ngo Casi, Cara L. Benjamin, Murat V. Kalayoglu(Unknown), Luis de la Cruz‐Merino
The Lancet Neurology
June 21, 2023
Cited by 255


Related Papers